Kinase inhibitors have recently emerged as a potential therapy for TP53-mutated AML, including inhibitors of casein kinase II (20), Polo-like kinase 4 (21), and spleen tyrosine kinase (22). The gene discussed is TP53; the disease is acute myeloid leukemia.